StockNow
Log in
U.S. Markets

Biogen (BIIB) announced topline results from the Phase 2 CELIA study evaluating diranersen; CELIA did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at Week 76

News detail

Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development. VP says: "We are excited by these Phase 2 data, which give us the confidence to advance diranersen to registrational development".

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)